Clopidogrel
Product Images NDC 33261-987

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 33261-987). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Clopidogrel 75mg Tab For Aurobindo 1)

Chemical structure of Clopidogrel, showing atoms such as carbon, hydrogen, oxygen, nitrogen, sulfur, and chlorine arranged in a specific molecular configuration. The image also indicates the presence of H2SO4 (sulfuric acid).*

FDA Label Image

Image Label (Clopidogrel 75mg Tab For Aurobindo 10)

Label for Clopidogrel 75 mg tablets by Aidarex Pharmaceuticals LLC, containing 90 film-coated tablets per container. The label specifies Clopidogrel bisulfate as the active ingredient and notes the product is generic for Plavix. Manufactured by Aurobindo Pharma Ltd. India, it includes dosage guidance spaces and NDC 33261-0987-90.*

FDA Label Image

Figure 1: Exposure To Clopidogrel Active Metabolite Following Multiple Doses Of Clopidogrel Bisulfate 75 mg Alone Or With Proton Pump Inhibitors (ppis) (Clopidogrel 75mg Tab For Aurobindo 2)

A horizontal error bar chart titled 'Exposure to Clopidogrel Active Metabolite Following Multiple Doses of Clopidogrel Bisulfate 75 mg Alone or with Proton Pump Inhibitors (PPIs).' The chart compares the effect on active metabolite AUC (mean and 90% confidence interval) with PPIs coadministered: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. The x-axis shows change relative to clopidogrel bisulfate administered alone, ranging from 0.4 to 1.4.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel 75mg Tab For Aurobindo 3)

A line chart titled 'Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study.' It compares cumulative event rates (%) for Placebo (+ aspirin) and Clopidogrel Bisulfate (+ aspirin) over 12 months of follow-up. The graph shows lower event rates for Clopidogrel Bisulfate compared to Placebo, with a p-value of 0.00009 indicating statistical significance.*

FDA Label Image

Figure 3: Hazard Ratio For Patient Baseline Characteristics And On-study Concomitant Medications/interventions For The Cure Study (Clopidogrel 75mg Tab For Aurobindo 4)

A forest plot chart titled "Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study." It compares Clopidogrel Bisulfate plus aspirin and placebo plus aspirin outcomes across various baseline characteristics and concomitant therapies, showing hazard ratios with 95% confidence intervals for each subgroup. The chart visualizes the relative effectiveness with markers indicating whether Clopidogrel or placebo is better.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study* (Clopidogrel 75mg Tab For Aurobindo 5)

A line graph titled 'Cumulative Event Rates for Death in the COMMIT Study' showing the percentage of deaths before first discharge over days since randomization (up to 28 days). It compares death rates between Clopidogrel and placebo groups, indicating a 7% proportional risk reduction with Clopidogrel. A footnote states all treated patients received aspirin.*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study* (Clopidogrel 75mg Tab For Aurobindo 6)

A line graph showing cumulative event rates for the combined endpoint of reinfarction, stroke, or death in the COMMIT study over 28 days. The y-axis represents the percentage with these events before first discharge. Two curves compare placebo (10.1% event rate) and clopidogrel (9.2% event rate), showing a 9% proportional risk reduction (p=0.002) for clopidogrel. A note indicates all treated patients received aspirin.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel 75mg Tab For Aurobindo 7)

A forest plot chart showing the effects of adding Clopidogrel Bisulfate to aspirin on the combined primary endpoint across baseline and concomitant medication subgroups from the COMMIT study. The chart compares event percentages and odds ratios with confidence intervals between Clopidogrel and placebo groups across various subgroups such as sex, age, time since onset, blood pressure, heart rate, fibrinolytic agent use, prognostic index, and metoprolol allocation.*

FDA Label Image

Figure 7: Effects Of Adding Clopidogrel Bisulfate To Aspirin In The Non-prespecified Subgroups In The Commit Study (Clopidogrel 75mg Tab For Aurobindo 8)

A forest plot figure titled 'Effects of Adding Clopidogrel Bisulfate to Aspirin in Non-Prespecified Subgroups in the COMMIT Study,' comparing events (%) and odds ratios between clopidogrel and placebo groups. It categorizes data by Killip class, previous myocardial infarction, and infarct location, showing odds ratio with confidence intervals and heterogeneity test results, including a proportional reduction labeled at 9%. The data visualizes subgroup treatment effects.*

FDA Label Image

Figure 8: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel 75mg Tab For Aurobindo 9)

A line graph titled 'Fatal or Non-Fatal Vascular Events' from the CAPRIE study. The x-axis represents months of follow-up (0 to 36), and the y-axis shows cumulative event rate percentage (0% to 16%). Two lines compare event rates between Aspirin and Clopidogrel Bisulfate, with Clopidogrel showing a slightly lower cumulative event rate over time. A p-value of 0.045 is indicated on the graph.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.